Results 181 to 190 of about 2,461 (207)

Vitreous concentration of topically applied brimonidine tartrate 0.2%

Ophthalmology, 2001
To determine the vitreous concentration of brimonidine after topical administration of Alphagan.Prospective observational case series.Eighteen patients scheduled for elective pars plana vitrectomy.Brimonidine tartrate, 0.2%, was topically administered twice or three times daily for 4 to 14 days preoperatively in 13 patients.
A R, Kent, J D, Nussdorf, R, David, F, Tyson, D, Small, D, Fellows   +5 more
openaire   +2 more sources

Side-Effect Profile of Brimonidine Tartrate in Children

Ophthalmology, 2005
To investigate brimonidine-related side effects and the efficacy of brimonidine in lowering intraocular pressure (IOP) in children with primary infantile and secondary glaucoma.Single-center, prospective, interventional, noncomparative case series.Eighty-three children (mean age, 7.84 years) met the inclusion criteria.Medical records were reviewed to ...
Sami, Al-Shahwan, Abdullah A, Al-Torbak, Shahira, Turkmani, Mamdouh, Al-Omran, Ibrahim, Al-Jadaan, Deepak P, Edward   +5 more
openaire   +2 more sources

Pupillometry Study of Brimonidine Tartrate 0.2% and Apraclonidine 0.5%

The Journal of Clinical Pharmacology, 2011
This study investigated possible effects of brimonidine tartrate 0.2% and apraclonidine 0.5% on pupil diameter. Ten subjects between 20 and 40 years of age participated. A Colvard pupillometer (Oasis Medical) was used to measure pupil diameter. Baseline and serial measurements were obtained at 3 luminance levels (>6.4,
Eulogio, Besada, Kimberly, Reed, Perla, Najman, Diana, Shechtman, Patrick, Hardigan   +4 more
openaire   +2 more sources

Effect of Brimonidine Tartrate on Ocular Hemodynamics in Healthy Volunteers

Journal of Ocular Pharmacology and Therapeutics, 2001
While alpha2-adrenergic agonists, such as brimonidine tartrate, significantly reduce the intraocular pressure (IOP), the presence of vasoconstrictor postsynaptic alpha2 receptors on vascular smooth muscle raise the possibility that brimonidine could potentially compromise ocular blood flow.
Jonescu-Cuypers, Christian Paul, Harris, A, Ishii, Y, Kagemann, L, Gazozi, H J, Rotenstreich, Y, Chung, H S, Martin, B   +7 more
openaire   +3 more sources

Effect of Brimonidine Tartrate 0.15% on Scotopic Pupil: Controlled Trial

Journal of Ocular Pharmacology and Therapeutics, 2007
The aim of this study was to evaluate the duration of the effect of one single dose of brimonidine tartrate 0.15% on pupil diameter, under scotopic conditions, when applied topically in 1 eye of normal subjects.The eyes of 19 normal volunteers were randomized so that 1 eye had 1 drop of brimonidine tartrate 0.15% and the other received no medication ...
Gerente, Vanessa M., Biondi, Adriano C., Barbosa, Carolina P., Lottenberg, Claudio L., Paranhos, Augusto   +4 more
openaire   +3 more sources

Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter

Journal of Cataract and Refractive Surgery, 2011
To evaluate the effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter under light and dark luminance conditions.Ophthalmology Department, Tel Aviv Medical Center, Tel Aviv, Israel.Case series.The pupil diameter was measured with a Colvard pupillometer in eyes of healthy volunteers under light (5.0 candelas [cd]/m(2)) and dark (0.0 ...
Gabi, Shemesh, Elad, Moisseiev, Moshe, Lazar, Anat, Kesler   +3 more
openaire   +2 more sources

Development and Evaluation of Novel Polymeric Nanoparticles of Brimonidine Tartrate

Current Drug Delivery, 2010
Micro and nanoparticulate carriers have been in focus in ophthalmic drug delivery with the objective of improving bioavailability, drug targeting and reducing pulse entry of the drug in ocular cul de sac. Polymeric nanoparticles for ocular purpose have potential in reducing the pulse entry and frequency of dosing, thus improving patient compliance.
Kavita H, Singh, Ujwala A, Shinde
openaire   +2 more sources

Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size

Journal of Cataract and Refractive Surgery, 2004
To evaluate the effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size under scotopic and photopic luminance conditions in persons considering laser refractive surgery.Ophthalmic Health Center, Tel Aviv, Israel.The pupil size was measured in 36 eyes of 36 participants under scotopic and photopic conditions using the Colvard pupillometer (
Anat, Kesler, Gabi, Shemesh, Levi, Rothkoff, Moshe, Lazar   +3 more
openaire   +2 more sources

Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use

Cornea, 2017
Purpose: The primary side effects associated with 0.1% brimonidine tartrate (BT) ophthalmic solution with sodium chlorite are allergic conjunctivitis, blepharitis, and conjunctival hyperemia. However, cornea-related side effects are rare.
Yuko, Maruyama, Yoko, Ikeda, Norihiko, Yokoi, Kazuhiko, Mori, Hiroaki, Kato, Morio, Ueno, Shigeru, Kinoshita, Chie, Sotozono   +7 more
openaire   +2 more sources

Vitreous and Aqueous Concentrations of Brimonidine Following Topical Application of Brimonidine Tartrate 0.1% Ophthalmic Solution in Humans

Journal of Ocular Pharmacology and Therapeutics, 2015
To determine the vitreous and aqueous concentrations of brimonidine after topical application of the ophthalmic solution 0.1%.The prospective observational case series included patients with an idiopathic epiretinal membrane or macular hole who were scheduled for a pars plana vitrectomy.
Yoshihiro, Takamura, Takeshi, Tomomatsu, Takehiro, Matsumura, Yuji, Takihara, Seiko, Kozai, Shogo, Arimura, Satoshi, Yokota, Masaru, Inatani   +7 more
openaire   +2 more sources